



Ironwood Pharmaceuticals to Host Fourth Quarter 2011 Investor Update Call

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Ironwood Pharmaceuticals, Inc.](http://www.ironwoodpharma.com) (NASDAQ: IRWD) today announced it will host its fourth quarter 2011 investor update conference call and webcast at 4:30 p.m. Eastern Time on Tuesday, February 28, 2012. Individuals interested in participating in the call should dial (888) 208-1812 (U.S. and Canada) or (719) 457-2702 (international) using conference ID number 3679648. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting February 28, 2012, at approximately 7:30 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on March 13, 2012. To listen to the replay, dial (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international) using conference ID number 3679648. The archived webcast will be available on Ironwood's website for 14 days beginning approximately one hour after the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is an investigational drug for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. The efficacy portion of linaclotide's development program has been completed and supports the recently submitted NDA submission for both indications, as well as the MAA submission in Europe for the IBS-C indication. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.

Ironwood Pharmaceuticals, Inc.

Susan Brady, 617.621.8304
Corporate Communications
sbrady@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

News Provided by Acquire Media